NLRP3 and myocardial infarction: Furthermore, NLRP3 protein levels in peripheral blood monocytes were found to be increased in patients with acute coronary syndrome and directly correlated with disease severity [110], whereas the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial clearly demonstrated the benefits of canakinumab, a monoclonal antibody targeting IL-1β, in terms of MACE reduction in patients with a previous myocardial infarction [111].